Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

513

HTML

3898

Figures (1-3)

288

Tables (1-3)

164

Sum=4863

Dec 6, 2012 (publication date) through Jul 31, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireview

World J Nephrol. Dec 6, 2012; 1(6): 184-194
Published online Dec 6, 2012. doi: 10.5527/wjn.v1.i6.184

Full Size Figure Download Figure

Figure 3 Protein isoprenylation and “pleiotropic” effects of statins[63-65]. HMG-CoA: 3-hydroxy-methyl-glutaryl-Coenzyme A.

Citation: Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J Nephrol 2012; 1(6): 184-194
URL: https://www.wjgnet.com/2220-6124/full/v1/i6/184.htm
DOI: https://dx.doi.org/10.5527/wjn.v1.i6.184